Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total

Not Applicable (1)

P 1 (1)

P 2 (1)

Trial Status

Unknown1

Completed1

Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials

NCT06773481Phase 1Recruiting

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

NCT02795364Not ApplicableUnknown

Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas

NCT01663012Phase 2Completed

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Showing all 3 trials

Glioblastomas (GBM)